Hazel Squires - Publications

Journal articles

Conference proceedings papers

  • Thomas C, Watson P, Greaves C, Squires H, Chilcott J & Brennan A (2014) Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. Value in Health, Vol. 17(7) (pp A347-A347)
  • Thomas C, Watson P, Squires H, Chilcott J & Brennan A (2014) Validation of the SPHR Diabetes Prevention Model. Value in Health, Vol. 17(7) (pp A556-A556)
  • Meng Y, Squires H, Stevens JW, Simpson E, Harnan S, Thomas S, Michaels J, Stansby G & O'Donnell M (2012) COST-EFFECTIVENESS OF CILOSTAZOL, NAFTIDROFURYL OXALATE, PENTOXIFYLLINE AND INOSITOL NICOTINATE FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN PEOPLE WITH PERIPHERAL ARTERIAL DISEASE IN THE UK. VALUE IN HEALTH, Vol. 15(7) (pp A633-A633)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND FOLLOW-UP OF COLORECTAL CANCER. VALUE IN HEALTH, Vol. 14(7) (pp A469-A470)
  • Tappenden P, Brennan A, Chilcott J & Squires H (2011) A METHODOLOGICAL FRAMEWORK FOR DEVELOPING MODELS OF WHOLE DISEASE AREAS TO INFORM RESOURCE ALLOCATION DECISIONS. VALUE IN HEALTH, Vol. 14(7) (pp A243-A243)
  • Jewitt K, Pilgrim H & Ward S (2008) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 141 (pp 38-38)
  • Pilgrim H, Jewitt K & Ward S (2007) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.. BLOOD, Vol. 110(11) (pp 376B-376B)

Other